Direct-acting antiviral agents do not increase the incidence of hepatocellular carcinoma development: a prospective, multicenter study-Reference-Cited by-同舟云学术

Direct-acting antiviral agents do not increase the incidence of hepatocellular carcinoma development: a prospective, multicenter study

Published:2019-02-28 Issue:3 Volume:13 Page:293-301
ISSN:1936-0533
Container-title:Hepatology International
language:en
Short-container-title:Hepatol Int

Author:

Ide Tatsuya,Koga Hironori^ORCID,Nakano Masahito,Hashimoto Satoru,Yatsuhashi Hiroshi,Higuchi Nobito,Nakamuta Makoto,Oeda Satoshi,Eguchi Yuichiro,Shakado Satoshi,Sakisaka Shotaro,Yoshimaru Yoko,Sasaki Yutaka,Honma Yuichi,Harada Masaru,Seike Masataka,Maeshiro Tatsuji,Miuma Satoshi,Nakao Kazuhiko,Mawatari Seiichi,Ido Akio,Nagata Kenji,Matsumoto Shuichi,Takami Yuko,Sohda Tetsuo,Kakuma Tatsuyuki,Torimura Takuji

Publisher

Springer Science and Business Media LLC

Subject

Hepatology

Link

http://link.springer.com/article/10.1007/s12072-019-09939-2/fulltext.html

Reference22 articles.

1. Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol. 2014;61:S45–S57.

2. Hiramatsu N, Oze T, Takehara T. Suppression of hepatocellular carcinoma development in hepatitis C patients given interferon-based antiviral therapy. Hepatol Res. 2015;45:152–161.

3. Tanaka Y, Nishida N, Sugiyama M. Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: Analysis of phase III ION trials. Hepatology. 2015;62:25–30.

4. Kwo P, Gitlin N, Nahass R, Bernstein D, Etzkorn K, Rojter S, et al. Simeprevir plus sofosbuvir (12 and 8 weeks) in HCV genotype 1-infected patients without cirrhosis: OPTIMIST-1, a phase 3, randomized study. Hepatology. 2016;64:370–380.

5. Pol S, Lucier S, de Lédinghen V, Zoulim F, Dorival-Mouly C, et al. Safety and efficacy of the combination daclatasvir-sofosbuvir in HCV genotype 1-monoinfected patients. J Hepatol. 2017;66:39–47.

Cited by 42 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Risk of hepatocellular carcinoma occurrence after antiviral therapy for patients with chronic hepatitis C Infection: a systematic review and meta-analysis;Hepatology International;2024-07-05

2. Hepatocellular carcinoma in hepatitis C virus patients treated with direct acting antivirals (DAAs) and patients not exposed to DAAs: a large center comparative study;Egyptian Journal of Radiology and Nuclear Medicine;2024-05-03

3. Characterization of circulating miRNAs in the treatment of primary liver tumors;Cancer Reports;2023-12-25

4. Metabolic management after sustained virologic response in elderly patients with hepatitis C virus: A multicenter study;Hepatology Research;2023-11-28

5. A novel formula used for predicting hepatocellular carcinoma after the achievement of sustained virologic response by direct-acting antivirals in patients with chronic hepatitis C;PLOS ONE;2023-09-21